| Print
Biodexa Pharmaceuticals plc (BDRX)
American Depository ReceiptThis share can be held in a Dealing account
Company profile
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasivebladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Address
65 Innovation Drive
Milton Park
Abingdon
Oxfordshire
GBR
OX14 4RQ
Telephone
+44 1235888300
Forecast key dates
| Name | Key Date |
|---|
Previous key dates
| Name | Key Date |
|---|---|
| Biodexa Pharmaceuticals Plc Annual General Meeting for 2025 | 2025-06-13T12:00:00 |
| Biodexa Pharmaceuticals Plc Annual Report for 2024 | 2025-05-15T00:00:00 |
| Biodexa Pharmaceuticals Plc Fourth Quarter Earnings Results for 2024 | 2025-04-18T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.